NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
6.07
-0.95 (-13.53%)
At close: May 27, 2026, 4:00 PM EDT
6.31
+0.24 (3.95%)
After-hours: May 27, 2026, 6:52 PM EDT
NextCure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
21.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Palatin Technologies | 12.88M |
| Marker Therapeutics | 3.55M |
| Traws Pharma | 2.73M |
| Pluri | 1.08M |
| Vistagen Therapeutics | 789.00K |
| Allarity Therapeutics | 345.00K |
NXTC News
- 16 days ago - NextCure initiated with a Buy at Lucid Capital - TheFly
- 20 days ago - NextCure reports Q1 EPS ($1.87), consensus ($2.03) - TheFly
- 20 days ago - NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 20 days ago - NextCure Quarterly report: Q1 2026 - Filings
- 20 days ago - NextCure Earnings release: Q1 2026 - Filings
- 20 days ago - NextCure Slides: Corporate presentation - Filings
- 23 days ago - NextCure initiates dose optimization portion of SIM0505 study - TheFly
- 23 days ago - NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - GlobeNewsWire